EGFR and glioblastoma: Classical GBM is characterised by EGFR amplification or mutations together with TP53 mutations [122], while mesenchymal GBM is characterised by NF1 inactivation, which abolishes the GTPase-activating function of neurofibromin, resulting in constitutive Ras-GTP loading [123].